Overview

Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)

Status:
Recruiting

Trial end date:
2021-07-15

Target enrollment:

Participant gender:

Summary

The investigators propose a prospective, randomized, double-blind, placebo-controlled study, conducted in two phases. The purpose of the study is to evaluate the safety and efficacy of methotrexate in a cholesterol-rich non-protein nanoparticle (MTX -LDE) in adults diagnosed with mild Coronavirus-19(COVID-19) disease. A total of 100 patients will be randomized to receive MTX-LDE or placebo each 7 days, up to 3 times, during in hospital treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Sao Paulo General Hospital

Collaborator:

Hospital Santa Marcelina

Treatments:

Methotrexate